CoChat

Glucagon receptor antagonism induces increased cholesterol absorption

Open access

The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.

Abstract

Glucagon and insulin have opposing action in governing glucose homeostasis. In type 2 diabetes mellitus (T2DM), plasma glucagon is characteristically elevated, contributing to increased gluconeogenesis and hyperglycemia. Therefore, glucagon receptor (GCGR) antagonism has been proposed as a pharmacologic approach to treat T2DM. In support of this concept, a potent small-molecule GCGR antagonist (GRA), MK-0893, demonstrated dose-dependent efficacy to reduce hyperglycemia, with an HbA1c reduction of 1.5% at the 80 mg dose for 12 weeks in T2DM. However, GRA treatment was associated with dose-dependent elevation of plasma LDL-cholesterol (LDL-c). The current studies investigated the cause for increased LDL-c. We report findings that link MK-0893 with increased glucagon-like peptide 2 and cholesterol absorption. There was not, however, a GRA-related modulation of cholesterol synthesis. These findings were replicated using structurally diverse GRAs. To examine potential pharmacologic mitigation, coadministration of ezetimibe (a potent inhibitor of cholesterol absorption) in mice abrogated the GRA-associated increase of LDL-c. Although the molecular mechanism is unknown, our results provide a novel finding by which glucagon and, hence, GCGR antagonism govern cholesterol metabolism.

Overview

Integrity signals

Registry

Crossref · 10.1194/jlr.m060897

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 55 references

Research works printed but not linked: 6

  1. Engel, 2011, Efficacy and tolerability of MK-0893, a glucagon receptor antagonist (GRA), in patients with type 2 diabetes (T2DM), Diabetes., 60, A85
  2. Engel, 2012, Glycemic and lipid effects of the short-acting glucagon receptor antagonist MK-3577 in patients with type 2 diabetes, Diabetes., 61, A266
  3. Kazda, 2013, The glucagon receptor antagonist LY2409021 significantly lowers HbA1c and is well tolerated in patients with type 2 diabetes mellitus: a 24-week phase 2 study, Diabetologia., 56, S391
  4. Morgan, 2014, ISIS-GCGRRX, an antisense glucagon receptor antagonist, caused rapid, robust, and sustained improvements in glycemic control without changes in BW, BP, lipids, or hypoglycemia in T2DM patients on stable metformin therapy, Diabetes., 63, LB28
  5. Engel, 2011, Efficacy and safety of the glucagon receptor antagonist, MK-0893, in combination with metformin or sitagliptin in patients with type 2 diabetes mellitus, Diabetologia., 54, S86
  6. Drucker, 2001, Glucagon-like peptide 2, J. Clin. Endocrinol. Metab., 86, 1759

Cited by

See all 80

Metadata

Authors
Guan, H.-P., Yang, X., Lu, K., Wang, S.-P., Castro-Perez, J. M., Previs, S., Wright, M., Shah, V., Herath, K., Xie, D., Szeto, D., Forrest, G., Xiao, J. C., Palyha, O., Sun, L.-P., Andryuk, P. J., Engel, S. S., Xiong, Y., Lin, S., Kelley, D. E., Erion, M. D., Davis, H. R., & Wang, L.
Affiliations
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Corresponding author
Guan, Hong-Ping
Venue
Journal of Lipid Research
Publisher
Elsevier BV
Published
2015-11
Volume
56
Issue
11
Pages
2183-2195
ISSN
0022-2275 (ISSN-L)
OpenAlex
W2179944903
Cited by
76
References
56
Citations by year
2025: 6 · 2024: 7 · 2023: 3 · 2022: 8 · 2021: 11 · 2020: 5 · 2019: 6 · 2018: 15 · 2017: 9 · 2016: 6
FWCI
10.07
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Lipid Research (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
type 2 diabetes, LDL cholesterol elevation, cholesterol absorption, ezetimibe, glucagon-like peptide-2, cholesterol metabolism, hyperglycemia, glucose homeostasis
MeSH terms
Animals, Cholesterol, Diabetes Mellitus, Type 2, Drug Evaluation, Preclinical, Humans, Hypercholesterolemia, Intestinal Absorption, Male, Mice, Inbred C57BL, Mice, Transgenic, Naphthalenes, Pyrazoles, beta-Alanine, Receptors, Glucagon, Inhibitory Concentration 50

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon receptor antagonism induces increased cholesterol absorption. https://app.cochat.ai/papers/10.1194/jlr.m060897
The paper
Guan, H.-P., Yang, X., Lu, K., Wang, S.-P., Castro-Perez, J. M., Previs, S., Wright, M., Shah, V., Herath, K., Xie, D., Szeto, D., Forrest, G., Xiao, J. C., Palyha, O., Sun, L.-P., Andryuk, P. J., Engel, S. S., Xiong, Y., Lin, S., . . . Wang, L. (2015). Glucagon receptor antagonism induces increased cholesterol absorption. Journal of Lipid Research. https://doi.org/10.1194/jlr.m060897

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.